Measuring Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors

Completed

Conditions studied: Breast Cancer

In brief

Current guidelines recommend endocrine treatment with aromatase inhibitors (AIs) in post-menopausal women with hormone receptor-positive breast cancer. Musculoskeletal symptoms are commonly reported with AI treatment,however, we do not have consistent methods to measure these symptoms prospectively. This gap in our knowledge inhibits the ability to test and develop treatments for AI-associated musculoskeletal symptoms. This pilot study will evaluate functional tests and standardized instruments for their ability to prospectively assess musculoskeletal symptoms in women being treated with AIs for breast cancer.

Key facts

Study ID

NCT01074320

Run by

HealthPartners Institute

People needed

150

Starts

2010-02-01

Expected to finish

2015-08-01

Last updated by the study team

2015-12-16

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Women with stage I - IIIa invasive breast cancer,
• Hormone-receptor positive cancer (either ER+ or PR+ or both),
• Prescribed and have agreed to take exemestane, anastrazole or letrozole,
• Have completed initial treatment of surgery, RT, and/or chemotherapy,
• Are post-menopausal,
• No previous history of aromatase inhibitor therapy for invasive breast cancer,
• Have signed the consent form.

You may not qualify if…

• History of rheumatoid arthritis,
• Unable to read or understand English,
• History of psychiatric disability affecting informed consent or compliance with study procedures.

Where it is running

• North Memorial Medical Center — Robbinsdale, Minnesota, United States
• Park Nicollet Institute — Saint Louis Park, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.